This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
CMS has published its final rule for the 2025 Medicare Physician Fee Schedule, and the 2025 conversion factor is down approximately 2.8% compared to 2024. Cardiology groups have been working hard to help stop these cuts since they were first proposed in July.
There’s no shortage of resources for healthcare workers who wish they knew AI well enough to talk shop with the technology pros who develop the models. The problem is weeding through the offerings to get to what will really work for you.
The Acurate neo2 TAVR valve has been used to treat severe aortic stenosis in other parts of the world for years. In the United States, however, the device has still not been approved for commercial use.
Sensors from the FreeStyle Libre 2 and Libre 3 continuous glucose monitoring systems can now be worn during X-rays, CT scans and MRI scans. The news represents a shift in policy from the FDA, one that came after the agency reviewed extensive testing data.
Discussions of AI governance may cause many an eye to glass over, but the discipline is as crucial to the ascent of AI in healthcare as big training datasets drawn from diverse patient populations.
One of the world's leading heart hospitals is seeing significant growth. This represents the first time it has hired four new cardiothoracic surgeons in a single 12-month period.
Americans trust nurses and doctors less than they did a few years ago, but both professions still make the top five among 23 wide and varied work roles.
The latest COVID-19 vaccine began entering recipients’ bodies last September. Now comes early CDC data supporting the formulation’s general effectiveness.
Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.
The approval, based on positive results from the TRISCEND II trial, represents a significant milestone for the treatment of severe tricuspid regurgitation.
Heart teams have several options when patients present with stable chest pain and require further testing. According to a brand new analysis of nearly 800 patients, CCTA may be the best place to start.
The nonprofit patient-safety organization says the list “reflects our judgment about which risks should be given attention now to help care providers, as well as device manufacturers, prioritize their patient safety efforts.”